Skip to main content

Table 2 Baseline characteristics of the study participants (after PSM)

From: Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score

Variables

Total (n = 42)

Matched cohort

  

cTACE (n = 21)

cTACE+MWA (n = 21)

p

Age, mean ± SD

59.0 ± 9.4

60.7 ± 9.9

57.3 ± 8.8

0.249

Sex, n (%)

   

1

 Female

3 (7.1)

2 (9.5)

1 (4.8)

 

 Male

39 (92.9)

19 (90.5)

20 (95.2)

 

HBV, n (%)

   

1

 No

5 (11.9)

3 (14.3)

2 (9.5)

 

 Yes

37 (88.1)

18 (85.7)

19 (90.5)

 

HCV, n (%)

   

1

 No

39 (92.9)

19 (90.5)

20 (95.2)

 

 Yes

3 (7.1)

2 (9.5)

1 (4.8)

 

AFP, n (%)

   

1

 <200ng/ml

27 (64.3)

14 (66.7)

13 (61.9)

 

 ≥200ng/ml

15 (35.7)

7 (33.3)

8 (38.1)

 

CP, n (%)

   

1

 A

39 (92.9)

19 (90.5)

20 (95.2)

 

 B

3 (7.1)

2 (9.5)

1 (4.8)

 

Tumor size, median (IQR)

3.4 (3.1, 4.1)

3.4 (3.1, 4.1)

3.5 (3.2, 4.1)

0.612

Portal hypertension, n (%)

   

1

 No

19 (45.2)

9 (42.9)

10 (47.6)

 

 Yes

23 (54.8)

12 (57.1)

11 (52.4)

 

PLT (×109/L), median

91.0 (67.2, 138.5)

88.0 (67.0, 137.0)

98.0 (70.0, 139.0)

0.772

TBIL (μmol/L), mean ± SD

13.3 ± 5.7

13.9 ± 6.4

12.7 ± 5.0

0.512

CRE (μmol/L), mean ± SD

66.6 ± 8.9

65.1 ± 8.6

68.0 ± 9.2

0.296

INR, mean ± SD

1.1 ± 0.1

1.1 ± 0.1

1.1 ± 0.1

0.653

  1. Notes: data presented are mean ± SD, median (Q1–Q3), and N (%)
  2. Abbreviations: HBV hepatic B virus, HCV hepatic C virus, AFP alpha-fetoprotein, CP Child-Pugh Classification, PLT platelet, TBIL total bilirubin, CRE creatinine, INR prothrombin time-international normalized ratio